Avandia (Rosiglitazone) May Increase Risk for Certain Heart Conditions

According to HealthDay (3/17, Dotinga), the BMJ study published online relating to Avandia (Rosiglitazone) reported that the study authors “examined the results of 16 studies that involved more than 800,000 patients” who used Actos or Avandia and found a “‘modest but statistically significant increase in the odds of certain heart conditions in those who took Avandia.” Specifically, the risk of  heart attack rose by 16 percent and increased 23 percent for congestive heart failure. Overall, mortality rates rose 14 percent.”